Rubbish Check
CNBC Top News · 2 August 2026 source

“AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports”

R2/ 10
Lightly altered
Rubbish Rating — 1 = base fact, 10 = pure rubbish
12345678910
In short
Rubbish Talk rates CNBC's headline that AstraZeneca and Bristol Myers Squibb are "in talks" on a $400 billion megadeal a 2/10 because the framing is accurately hedged, properly sourced to the FT, and matches how Reuters, Yahoo Finance and Benzinga independently reported the same story.
The Verdict
Base fact, lightly dressed. CNBC attributes the claim correctly to the FT throughout, uses the hedged "in talks" rather than declaring a done deal, and the body explicitly states the outcome is uncertain. The only iteration away from pure base fact is the word "megadeal" in the headline, a flourish rather than a distortion given the scale involved.

What actually happened

The Financial Times reported that AstraZeneca and Bristol Myers Squibb have held merger discussions over recent months that could value the combined company at roughly $400 billion. Reuters independently confirmed the FT report's substance, and both companies declined to comment when approached.

Key facts

  • Combined valuation cited: roughly $400 billion, per the FT's sourcing.
  • AstraZeneca's standalone market cap is approximately $263 billion to $264 billion; Bristol Myers Squibb's is around $133 billion, per multiple outlets citing the same figures.
  • Talks reportedly took place "over recent months," not a fresh development, and both companies declined to comment.
  • The report notes the deal "could materialise soon, but could also be delayed or fall apart" (Reuters); CNBC's own copy states "it's still unclear whether the deal will come together."
  • AstraZeneca's cancer treatments made about $25 billion in 2025 sales, and cardiovascular/renal/metabolism drugs about $12 billion, both from the company's own Q2 results.

What to watch for

Watch for confirmation or denial from either company, since neither has commented on the record. Antitrust exposure is a real follow-on risk given both firms' overlapping oncology portfolios, a point some other outlets flagged that CNBC's initial write-up did not dwell on. If a formal bid emerges, compare the eventual structure (cash vs. shares) against this early "talks" framing to see how much shifted.

About this scoreThe R-Score is Rubbish Talk's editorial opinion on how far a headline's framing sits from what the underlying facts support. It is a judgement about presentation and emphasis, not an allegation that any outlet has acted dishonestly. Every figure we rely on is linked under Receipts so you can check it yourself.
Share this CheckXFacebookLinkedInEmail